Video interview: Novartis discusses challenges around second medical use
The biggest challenges in the life sciences concern second medical use patents and incentives for innovation, according to Lydia McNally, vice president, head of patents, oncology at Novartis.
McNally was speaking on a panel at Life Sciences Patent Network North America, an event hosted by LSIPR in Boston in June.
The panel discussed the challenges in the area of second medical use patents, including the difficulty of obtaining and enforcing them.
McNally said there may be a need to “look beyond the patent system”, perhaps by introducing modifications to data exclusivity and assessing drug pricing.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk